CXCL10 and diabetes mellitus: In line with this hypothesis, administration of an antibody neutralizing CXCL10 following aCD3 treatment resulted in reduced CD8+ T-cell infiltration into pancreatic islets and increased remission of diabetes compared to aCD3 monotherapy in preclinical disease models [27].